- Biocon's Q1FY27 net profit rose 348.4% to Rs 141 crore from Rs 31.4 crore year ago
- Revenue increased 10% YoY to Rs 4,336 crore, with EBITDA margin stable at 19.53%
- Core Biopharma, including biosimilars and generics, drove the strong quarterly performance
Biocon reported strong growth in Q1FY27, with profit rising sharply and revenue crossing Rs 4,300 crore. The company reported a 348.4% year-on-year jump in consolidated net profit to Rs 141 crore for the quarter ended June 2026, compared with Rs 31.4 crore in the year-ago period.
Revenue from operations increased 10% YoY to Rs 4,336 crore, from Rs 3,942 crore in Q1FY26. The earnings before interest, taxes, depreciation and amortisation rose 10.6% to Rs 847 crore from Rs 766 crore, while the EBITDA margin was broadly stable at 19.53%, compared with 19.43% a year earlier.
The stronger quarter was led by Biocon's core Biopharma business, which includes biosimilars and generics. Biosimilars revenue rose 16% to Rs 2,855 crore, while generics revenue increased 21% to Rs 760 crore, as per the exchnage filings .
In contrast, the company's services business reported a 16% decline to Rs 736 crore, making the mix of growth an important factor for investors.
Also Read: Biocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead
Commenting on the results, Shreehas Tambe, CEO and Managing Director of Biocon, said the company delivered a resilient Q1FY27 performance, supported by its diversified portfolio and disciplined commercial execution.
He highlighted the launch of Bosaya and Aukelso, biosimilars of Denosumab, Yesafili, a biosimilar of Aflibercept, and generic Liraglutide, which have strengthened Biocon's presence in the US market.
Tambe also pointed to the European Medicines Agency's approval for Biocon's new drug-product fill-finish plant for insulin in Malaysia. The approval gives the company additional manufacturing capacity and supports its strategy of expanding its insulin business.
Kiran Mazumdar-Shaw, Executive Chairperson of the company, also stated that Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars, together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market.
She also mentioned that we remain confident that the investments in new capabilities at our research services business will support its next phase of growth.
In today's trading session, Biocon shares were at Rs 425.20, up 0.76% at 3:30 pm on August 5. The stock touched an intraday high of Rs 428.65 and a low of Rs 422.30, against the previous close of Rs 422.00.
Also Read: Biocon Shares Rise After Mylan's Exit Following Rs 3,676-Crore Stake Sale
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.